Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Jan 15;13(2):300.
doi: 10.3390/cancers13020300.

Prognostic and Predictive Values of Mismatch Repair Deficiency in Non-Metastatic Colorectal Cancer

Zhaohui Jin  1 , Frank A Sinicrope  1
Affiliations
Review

Prognostic and Predictive Values of Mismatch Repair Deficiency in Non-Metastatic Colorectal Cancer

Zhaohui Jin et al. Cancers (Basel). .

Abstract

Colorectal cancer (CRC) is the third most commonly diagnosed cancer worldwide. Universal MMR/MSI testing is standard of care for all patients with newly diagnosed CRC based on multi-society guidelines in the United States. Such testing is intended to identify patients with Lynch Syndrome due to a germline mutation in an MMR gene, but also detects those with sporadic dMMR/MSI-high CRCs. The prognostic utility of MMR/MSI status in non-metastatic colorectal cancer has been studied extensively, yet more limited data are available for its predictive utility. Results have not been entirely consistent due to potential stage-related differences and limited numbers of dMMR/MSI-H patients included in the studies. In this review, we summarize the current evidence for the prognostic and predictive value of dMMR/MSI-H in non-metastatic CRC, and discuss the use of this biomarker for patient management and treatment decisions in clinical practice.

Keywords: microsatellite instability; mismatch repair deficiency; non-metastatic colorectal cancer; predictive; prognostic.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

References

    1. GBD 2017 Colorectal Cancer Collaborators The global, regional, and national burden of colorectal cancer and its attributable risk factors in 195 countries and territories, 1990–2017: A systematic analysis for the Global Burden of Disease Study 2017. Lancet Gastroenterol. Hepatol. 2019;4:913–933. doi: 10.1016/S2468-1253(19)30345-0. - DOI - PMC - PubMed
    1. Siegel R.L., Miller K.D., Goding Sauer A., Fedewa S.A., Butterly L.F., Anderson J.C., Cercek A., Smith R.A., Jemal A. Colorectal cancer statistics, 2020. CA Cancer J. Clin. 2020;70:145–164. doi: 10.3322/caac.21601. - DOI - PubMed
    1. Jenkins M.A., Hayashi S., O’Shea A.M., Burgart L.J., Smyrk T.C., Shimizu D., Waring P.M., Ruszkiewicz A.R., Pollett A.F., Redston M., et al. Pathology features in Bethesda guidelines predict colorectal cancer microsatellite instability: A population-based study. Gastroenterology. 2007;133:48–56. doi: 10.1053/j.gastro.2007.04.044. - DOI - PMC - PubMed
    1. Bessa X., Alenda C., Paya A., Alvarez C., Iglesias M., Seoane A., Dedeu J.M., Abuli A., Ilzarbe L., Navarro G., et al. Validation microsatellite path score in a population-based cohort of patients with colorectal cancer. J. Clin. Oncol. 2011;29:3374–3380. doi: 10.1200/JCO.2010.34.3947. - DOI - PubMed
    1. Cancer Genome Atlas N. Comprehensive molecular characterization of human colon and rectal cancer. Nature. 2012;487:330–337. doi: 10.1038/nature11252. - DOI - PMC - PubMed

LinkOut - more resources